For example, mutations in NPM1, FLT3-ITD, and c-KIT, as well as aberrant expression of BCL-2, MN1, WT1, and MDR1 provide some clues for evaluating the prognosis of AML patients3–5. This evidence concerns the gene ABCB1 and acute myeloid leukemia.